Candel Therapeutics Says One Dose Of CAN-3110 Shows Encouraging Responses In A Type Of Brain Cancer

Candel Therapeutics Inc CADL announced new data from an ongoing phase 1 trial of its herpes simplex virus-1 (HSV-1) replication-competent viral immunotherapy candidate, CAN-3110, in patients with high-grade glioma that has recurred after standard of care (SoC) treatment. 

Glioma is a type of tumor that occurs in the brain and spinal cord.

The company previously announced data from arm A (n=41), demonstrating that treatment with a single dose of CAN-3110 was generally well tolerated and resulted in median overall survival (mOS) rate of 11.6 months as of the data cutoff date on July 22, 2022. 

This has now been updated to 11.8 months as of the data cutoff date on April 20, 2023. 

New clinical data from arm B (n=9) and updated data from arm A demonstrated:

CAN-3110 was well tolerated without dose-limiting toxicities.

mOS in arm B is ongoing at 12.0 months and supports the encouraging clinical activity of CAN-3110 observed in arm A.

Responses were observed in injected and uninjected lesions in patients with multifocal disease.

In addition to the two patient case studies disclosed from arm A, one patient from arm B exhibited a continued reduction in tumor volume approximately one year after CAN-3110 treatment. 

Extensive biomarker studies, including histology, transcriptomics, and single-cell sequencing, are ongoing.

Price Action: CADL shares are down 7.38% at $1.58 on the last check Friday.